Recombinant factor VIIa: A new treatment of haemophilia;Le facteur VII active recombinant: Un nouveau traitement de l'hemophilie

Transfusion Clinique et Biologique

Volumn 5, Issue 4, 1998, Pages 260-265

  Goudemand, J ^a  

^a UNIV LILLE   (France)

Author keywords

Haemophilia; Haemorrhages; Inhibitor; Recombinant FVIIa; Surgery

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; HYBRID PROTEIN;

ANIMAL CELL; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEMOPHILIA; HUMAN; NONHUMAN; ANIMAL; CELL LINE; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HAMSTER; HEMOPHILIA A; ISOLATION AND PURIFICATION; KIDNEY; MALE; METABOLISM; PHYSIOLOGY; REVIEW; SYRIAN HAMSTER;

ANIMALS; BLOOD LOSS, SURGICAL; CELL LINE; CLINICAL TRIALS; CRICETINAE; ENZYME ACTIVATION; FACTOR VIIA; FACTOR X; HEMOPHILIA A; HUMANS; KIDNEY; MALE; MESOCRICETUS; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 0032140169     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(98)80404-7     Document Type: Article

References (15)

1. 1 Goudemand J. Hémophilies. Encycl Méd Chir (Elsevier, Paris). Hématologie 13-021-13-10. 1997 : 18p
2. 2 Telgt DSC, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989 ; 56 : 603-9
3. 3 Morten Sandset P, Abildgaard U, Hedner U, Johansson H. Extrinsic coagulation pathway inhibitor during recombinant factor VIIa infusion. Thromb Haemostas 1989 ; 62 : 1146
4. 4 Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of Factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused Factor VIIa. Blood 1990 ; 75 : 1069-73
5. 5 Monroe DM, Hoffman M, Oliver J, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99 : 542-7
6. 6 Thim L, Bjoern S, Christiansen M et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988 ; 27 : 7785-93
7. 7 Hedner U, Kiesel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983 ; 71 : 1386-41
8. 8 Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patients with severe haemophilia A during synovectomy [letter]. Lancet 1988 ; 2 : 1193
9. 9 Macik BG, Hohneker J, Roberts HR et al. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989 ; 32 : 232-4
10. 10 Macik BG, Lindley CM, Lusher J et al. Safety and initial clinical efficacy of three dose levels of recombinant factor VII (rFVIIa). Results of a phase I study. Blood Coagul Fibrinolysis 1993 ; 4 : 521-7
11. 11 Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994 ; 55 : 638-48
12. 12 Lusher JM and the NovoSeven® Compassionate Use Investigators. Recombinant factor VIIa (NovoSeven® in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996 ; 26 (suppl 1) : 124-30
13. 13 Laurian Y, Goudemand J, Négrier C et al. Use of NovoSeven® as first line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (Nosepac study). American Society of Haematology ; December 1997 ; San Diego
14. 14 Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996 ; 26 (suppl 1) : 118-23
15. 15 Schulman S, Bech Jensen M, Varon D et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996 ; 75 : 432-6